PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Visiongain

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

OTC Pharma Market to Reach $80.7 Billion in 2014 Visiongain Report Predicts - A new report by visiongain predicts that the world market for over-the-counter (OTC) medicines will reach $80.7 billion for 2014. That revenue forecast appears in World OTC Pharmaceutical Market 2012-2022, published in June 2012 - Visiongain.com
OTC Pharma Market to Reach $80.7 Billion in 2014 Visiongain Report Predicts

 

NewswireToday - /newswire/ - London, United Kingdom, 2012/06/12 - A new report by visiongain predicts that the world market for over-the-counter (OTC) medicines will reach $80.7 billion for 2014. That revenue forecast appears in World OTC Pharmaceutical Market 2012-2022, published in June 2012 - Visiongain.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Visiongain forecasts that the overall market for OTC pharmaceuticals will grow steadily from 2012 to 2022. In recent years, revenues from consumer healthcare products have outgrown those from prescription (Rx) drugs. The high worldwide demand for OTC medicines benefits from demographic trends, emerging economies, awareness about self-medication and expanding channels of distribution, the study notes.

Dr Syed Ahmed, a senior healthcare industry analyst in visiongain, explains: “Self-medication is becoming increasingly popular. People worldwide rely on over-the-counter products for medical needs ranging from pain, flu, headaches and allergies to contraception, skin care, weight control and hair re-growth. The OTC market will achieve high revenue growth to 2022, stimulated in particular by Rx-to-OTC switches, other reformulations and rising demand in developing countries.
“In particular, the cough, cold and allergy market segment will perform strongly to 2022. The recent Allegra Rx-to-OTC switch has boosted the sector. Product launches and strong performance from existing brands will sustain high revenue growth this decade for consumer health companies. Innovative marketing and promotional campaigns will help those organisations, with Web 2.0 playing its part.”

There is a trend for companies to move some drugs from prescription-only to OTC availability (Rx-OTC switching) as part of product lifecycle management, the report observes. That trend is also attractive to consumers and healthcare providers. OTC medicines are generally priced lower than prescription drugs. Also, many consumers welcome the easier availability of OTC medicines, freeing themselves from the need to visit a doctor, especially if the ailment is non-serious or embarrassing.

Visiongain’s report provides revenue forecasts to 2022 at world market, therapeutic submarket, product and national level. It forecasts world sales for the following submarkets:

• Analgesics/pain relievers;
• Gastrointestinal agents;
• Dermatological treatments;
• Smoking cessation products;
• Other medications in consumer healthcare.

Analyses exclude vitamins, minerals and other nutritional products. The investigation predicts sales of leading products in the OTC market, including Tylenol, Nicorette, Panadol and Advil. Research, data and analyses cover activities of Johnson & Johnson, GlaxoSmithKline, Bayer, Procter & Gamble and other healthcare companies.

The study discusses brand extensions and commercial news, shows research interviews with external authorities and forecasts revenues in leading national markets. The work analyses markets in the US, Japan, leading EU countries, China and India.

World OTC Pharmaceutical Market 2012-2022 adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For sample pages and further information concerning the visiongain report World OTC Pharmaceutical Market 2012-2022, please visit the website.

About Visiongain
Visiongain (visiongainglobal.com) is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Visiongain

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


OTC Pharma Market to Reach $80.7 Billion in 2014 Visiongain Report Predicts

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Sara Peerun - Visiongain.com 
+44(0)20 7336 6100 sara.peerun[.]visiongainglobal.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Visiongain securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Visiongain / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)